Nuevocor, a pre-clinical stage biotechnology company, announced on Thursday that it has named Dr John Lee, MD, PhD, as its new chief Medical officer.
Dr Lee, a life science executive, has more than 15 years of clinical development and regulatory experience from early drug discovery to late-stage clinical development. He has most recently served as the chief medical officer of PhaseBio Pharmaceuticals. He has served as vice president, global head, Cardiovascular Center of Excellence at Quintiles and executive director, Discovery Medicine at Bristol-Myers Squibb, and has served in leadership roles in both biotech and pharmaceutical sectors.
Dr Yann Chong Tan, PhD, CEO and co-founder of Nuevocor, said, 'Dr Lee's appointment marks a significant milestone for Nuevocor. His extensive experience and proven track record in clinical development make him the ideal candidate to lead our clinical development team. His leadership will be instrumental in furthering our commitment to advancing science and translating it into therapies that will make a real difference in patients' lives.'
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Xylyx Bio receives SBIR grant from NIDDK
Anervea.ai names new chief commercial officer and board member
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics